Portal de Periódicos da CAPES

National Consensus for Screening, Diagnosis and Management of Hepatocellular Carcinoma in Panama, 2022

2022; Openventio Publishers; Volume: 7; Issue: 1 Linguagem: Inglês

10.17140/csmmoj-7-133

2377-1518

Moisés Cukier, José M. Cabada-Lee, Jorge David Mendez-Rios, R Torres Arauz, Erik Araúz, Norberto Carreño, Ivette Clavel, Jan A. Cubilla-Rodríguez, Dafnia De Gracia, Iván Díaz, Olivia El Achtar, Kenia Franco, Julissa Lobardo-Quezada, Yong Loo, Melisa I. Menéndez, Gaspar Pérez-Jiménez, José Pinto-Llerena, Lizka Richards-Cantora, Mauricio Rodríguez-Bravo, M Fernandez Ruiz, Karen E. Suñé, Ignacio Véliz, Ruth Vergara-Vásquez,

Global Public Health Policies and Epidemiology

Introduction Hepatocellular carcinoma (HCC) is considered the main primary neoplasm of the liver and its incidence is expected to increase in the next years. HCC is frequently associated with chronic liver disease secondary to hepatitis B or C infections, as well to alcohol abuse, fatty liver and metabolic syndrome. Multidisciplinary and individualized management has been shown to improve clinical outcome; nevertheless, in Panama and others Latin-American countries, there is no clear consensus for the management of this disease. Methodology Using Appraisal of Guidelines for REsearch and Evaluation II (AGREE II) methodology and the Institute of Medicine (IOM) criteria, we developed a multidisciplinary consensus for the management of hepatocarcinoma patients in Panama. Results This document synthesizes the current evidence on risk factors in conjunction with recommendations on the management of early, advanced and terminal disease. All healthcare personnel involved in the approach and treatment of hepatocarcinoma in Panama can find utility and applicability in their daily practice. Conclusion Here, we present the first National Consensus for the Screening, Diagnosis and Treatment of Hepatocellular Carcinoma in Panama